Pfizer- Understanding Healthcare Disparities in Atopic Dermatitis and Alopecia Areata Patients

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire with Unit

Memorial Deadline: Tuesday 14th, September 2021

External Deadline: Friday 17th, September 2021


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.
For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Clinical Area: Atopic Dermatitis (AD) and/or Alopecia Areata (AA)

Link to full RFP: Understanding Healthcare Disparities in Atopic Dermatitis and Alopecia Areata Patients

Application Due Date: September 10, 2021

Specific Area of Interest: Projects to be considered for Pfizer support will focus on understanding healthcare disparities among underrepresented populations in AD and/or AA patients with a special emphasis on improving care standards, healthcare resources access and utilization.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: August 17, 2021